Full-Time

Manager Platform Solution Development

Business Analysts

Updated on 8/13/2026

RELX

RELX

1,001-5,000 employees

Global information analytics and decision tools

Compensation Overview

$118.3k - $219.8k/yr

+ Annual incentive bonus

Company Historically Provides H1B Sponsorship

Alpharetta, GA, USA

Hybrid

Three days in the office per week are expected.

Bachelor's, Master's, MBA

Category
Business & Strategy (1)
Required Skills
REST APIs
Data Analysis

Get referred to RELX

See people who can refer or advise you

Requirements
  • At least 8 years of experience in business analysis, solution development, product solution leadership, or a related discipline.
  • Experience developing and executing complex requirements and solution designs across enterprise-scale systems.
  • A track record of hiring, developing, coaching, and managing people, ideally including Business Analysts.
  • A Bachelor's or Master's degree in a technical subject such as Computer Science or Engineering, or in a business discipline, is preferred but not required.
  • Strong understanding of business analysis practices, requirements lifecycle management, solution design, documentation standards, and traceability.
  • Experience onboarding products, services, and features onto enterprise platforms and translating business needs into scalable solution designs.
  • Understanding of application programming interfaces, integration patterns, data models, Extensible Markup Language, JavaScript Object Notation, workflow automation, low-code capabilities, and modern platform architectures.
  • Experience working across monolithic and modernized technology environments.
  • Ability to use data, key performance indicators, and structured analysis to guide decisions, identify trends and risks, and improve outcomes.
  • Strong communication, active listening, stakeholder management, and influencing skills across business and technology audiences.
  • Ability to navigate conflict constructively, build trust, create alignment, and drive outcomes in cross-functional environments.
  • Demonstrated ability to set expectations, create accountability, motivate teams, and deliver against goals and performance metrics.
  • Commitment to continuous improvement, innovation, self-development, and building sustainable high-performing teams.
Responsibilities
  • Lead the end-to-end solution lifecycle by aligning customer needs, business priorities, and platform capabilities.
  • Define strategy and roadmap priorities that balance business value, delivery efficiency, and technical constraints.
  • Drive solution decisions that support scalable, reusable, platform-aligned outcomes.
  • Lead the creation and management of requirements artifacts, including user stories, process flows, and functional specifications.
  • Ensure strong documentation standards, requirements traceability, and alignment between business needs and technical delivery.
  • Build and evolve the Business Analysis function by setting standards, coaching analysts, improving practices, and developing team capability.
  • Hire, develop, coach, and manage Business Analysts with a focus on accountability, sustainable performance, and delivery quality.
  • Communicate clearly, actively listen, build trust, and align cross-functional stakeholders across business, product, engineering, operations, and support.
  • Translate complex business needs into actionable solution designs and explain technical concepts to technical and non-technical audiences.
  • Use data, key performance indicators, and structured analysis to guide solution decisions, identify trends and risks, and improve solution quality and delivery outcomes.
  • Apply technical and platform understanding of application programming interfaces, data models, integration patterns, Extensible Markup Language, JavaScript Object Notation, workflow automation, low-code capabilities, and modern platform architectures.
  • Work across monolithic and modernized technology environments to support platform modernization and operational enablement initiatives.
  • Set clear expectations, create accountability, motivate teams, and drive delivery against defined goals and performance metrics.
  • Navigate conflict constructively, influence decisions, and drive outcomes in complex cross-functional environments.
  • Foster innovation and continuous improvement by identifying high-impact opportunities and improving requirements practices, processes, and solution delivery approaches.
  • Take ownership of personal growth by seeking feedback, learning from experience, leveraging networks, and aligning development plans with evolving business needs.
Desired Qualifications
  • A Master of Business Administration or management degree.

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Get referred to RELX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • RELX grew H1 2026 revenue 7% and adjusted operating profit 9%.
  • RELX announced Doctrine on April 28, 2026, expanding multilingual legal AI across Europe.
  • Risk Solutions and Legal keep hiring; Mike Walsh took Risk CEO on July 1, 2026.

What critics are saying

  • Anthropic-style legal AI tools commoditize research, pressuring LexisNexis pricing during 2026.
  • Doctrine needs EU approvals and integration; failed execution wastes RELX's European AI push.
  • Exhibitions still faces event timing and Middle East disruption, hurting 2026 revenue visibility.

What makes RELX unique

  • RELX combines proprietary datasets with AI workflows across Legal, Risk, STM, and Exhibitions.
  • LexisNexis owns 200 billion legal documents, including Shepard's Citations dating to 1873.
  • Recurring subscriptions and high switching costs protect margins across mission-critical professional workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

Citybiz
Apr 28th, 2026
RELX to Acquire Legaltech Platform Doctrine in European AI Push

RELX Group has entered into an agreement to acquire French legal technology company Doctrine, a move that would expand its... Read More

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence